In a report released today, Lauren Lieberman from Barclays maintained a Hold rating on Kenvue, Inc. (KVUE – Research Report), with a price target of $21.00. The company’s shares closed last ...

Kenvue's stock has underperformed since its IPO, with disappointing guidance cuts for 2023 and 2024, and minimal growth projected for 2025. Despite recent struggles, Kenvue's strong brand ...

J.P. Morgan analyst Andrea Faria Teixeira maintained a Buy rating on Kenvue, Inc. (KVUE – Research Report) on February 6 and set a price target of $24.00. The company’s shares closed yesterday ...

On Monday, William Blair reaffirmed a Market Perform rating on Kenvue Inc (NYSE:KVUE), a consumer health company with a market capitalization of $38.69 billion. According to InvestingPro data ...

SKILLMAN, N.J., February 06, 2025--Kenvue Inc. (NYSE: KVUE), today announced financial results for the full year and fiscal fourth quarter ended December 29, 2024. We recently published a list of ...

SKILLMAN, N.J., February 06, 2025--Kenvue Inc. (NYSE: KVUE), today announced financial results for the full year and fiscal fourth quarter ended December 29, 2024 ...

One such firm that I came across is none other than Kenvue (KVUE). This is a business that operates as the world's largest pure play consumer health company. This is a space that I have written ...

In appraisal of Kenvue’s visual identity, the logo for the independent new company is said to represent Johnson & Johnson’s timelessness, while “allowing space for its iconic brands to have ...